Qyuns Therapeutics Co., Ltd. is a clinical biopharmaceutical company focusing on biotherapeutics for autoimmune and allergic diseases. The company is headquartered in Taizhou, Jiangsu and currently employs 337 full-time employees. The company went IPO on 2024-03-20. The firm is mainly engaged in biotechnology research and development of biological therapies for autoimmune and allergic diseases. The firm's business mainly covers four major disease areas, including skin, rheumatism, respiratory and digestive tract diseases. The firm is developing eight projects, with target indications including psoriasis, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disease and asthma. The firm's core products include QX002N and QX005N.
02509.HK stock price ended at $20.64 on 星期五, after rising 4.24%
On the latest trading day Feb 13, 2026, the stock price of 02509.HK rose by 4.24%, climbing from $19.52 to $20.64. During the session, the stock saw a volatility of 8.70%, with prices oscillating between a daily low of $19.30 and a high of $20.98. Notably, trading volume dropped by 139.8K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 259.4K shares were traded, equating to a market value of approximately $4.6B.